Abstract
Long non-coding RNAs (lncRNAs) are reported to participate in tumor development. It has been manifested in previous researches that lncRNA ELFN1-AS1 is involved in early-stage colon adenocarcinoma with potential diagnostic value. However, no studies have revealed the specific mechanism of ELFN1-AS1 in colon cancer, and there are no other studies on whether ELFN1-AS1 is associated with tumorigenesis. In our study, ELFN1-AS1 with high expression in colon cancer was selected by TCGA analysis, and the survival analysis was carried out to verify it. Subsequently, qRT-PCR was adopted for validating the results in tissues and cell lines. Cell counting kit-8 (CCK8), 5-ethynyl-2’-deoxyuridine (EdU), cell colon, cell apoptosis, cell cycle, cell migration, and invasion assays were utilized to assess the role of ELFN1-AS1 in colon cancer. Results uncovered that ELFN1-AS1 expression was prominently raised in colon cancer cells and tissues. ELFN1-AS1 decrement restrained cells to grow through interfering with distribution of cell cycle and promoting apoptosis. Meanwhile, ELFN1-AS1 decrement weakened the capacity of cells to migrate and invade. What’s more, ELFN1-AS1 was uncovered to act as a competing endogenous RNA (ceRNA) to decrease miR-191-5p expression, thus raising special AT-rich sequence-binding protein 1 (SATB1), a downstream target of ceRNA. To sum up, ELFN1-AS1 drives colon cancer cells to proliferate and invade through adjusting the miR-191-5p/SATB1 axis. The above results disclose that lncRNA ELFN1-AS1 is possibly a novel treatment target for colon cancer cases.
Highlights
The American Cancer Society statistics manifest that colon cancer has a incidence rate of 10.2% and a death rate of 9.2% in human, ascending from the fourth place to the second [1, 2]
Based on TCGA database analysis, ELFN1-AS1 with a high expression in colon cancer was selected as a research object (Figure 1A)
We found that only the expression of SATB1 was downregulated after miR-191-5p mimics transfection in SW620 cells (Figure 5B)
Summary
The American Cancer Society statistics manifest that colon cancer has a incidence rate of 10.2% and a death rate of 9.2% in human, ascending from the fourth place to the second [1, 2]. Colon cancer cases at the early stage are generally treated by tumor resection, and the combined therapy with chemotherapeutic drugs is usually applied in colon cancer cases at different stages, especially at the late stage [3]. These drugs include cytotoxic drugs (oxaliplatin, 5-fluorouracil, capecitabine and irinotecan) and biological agents (panitumumab, bevacizumab and cetuximab) [4, 5]. Liver metastasis arises at the time of first diagnosis in about 25% of colon cancer cases, and occurs within three years after first surgery in about 50% of them [8]. Investigation of the molecular mechanism of metastasis meets the clinical needs
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
